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Abstract We have previously validated a probabilistic
framework that combined computational approaches for
predicting the biological activities of small molecule drugs.
Molecule comparison methods included molecular struc-
tural similarity metrics and similarity computed from lex-
ical analysis of text in drug package inserts. Here we
present an analysis of novel drug/target predictions,
focusing on those that were not obvious based on known
pharmacological crosstalk. Considering those cases where
the predicted target was an enzyme with known 3D
structure allowed incorporation of information from
molecular docking and protein binding pocket similarity in
addition to ligand-based comparisons. Taken together, the
combination of orthogonal information sources led to
investigation of a surprising predicted relationship between
a transcription factor and an enzyme, specifically, PPARa
and the cyclooxygenase enzymes. These predictions were
confirmed by direct biochemical experiments which vali-
date the approach and show for the first time that PPARa
agonists are cyclooxygenase inhibitors.
Introduction
A number of interesting relationships between drugs and
novel targets have been uncovered by ligand-based
molecular similarity computations: methadone being
revealed as a muscarinic antagonist [1, 2], numerous
additional examples of ligand crosstalk among aminergic
GPCR receptor subtypes and between those receptors and
various transporters of amine-containing ligands [3, 4], and
examples that highlight less obvious relationships such as
the PARP inhibitor PJ34 specifically inhibiting Pim1
kinase [5]. In this work, we show how protein structural
information can be exploited to bolster predictions of
polypharmacology from ligand-based computations. The
approach combines data from molecular docking, protein
binding pocket similarity, 3D structural ligand similarity,
and ligand-similarity based on lexical analysis of drug
package inserts [6–9]. The combined computational
approach identified a clear chemical and structural linkage
between perixosome proliferator-activator receptor alpha
(PPARa) and the cyclooxygenase (COX) enzymes, which
share no sequence homology and have disparate in vivo
functions.
Given a particular query ligand (e.g. gemfibrozil, a
PPARa ligand), a prediction that it interacts with a new
target (the COX enzymes) is based on three types of
information: (1) chemical structures of ligands of the new
target, (2) textual patient package insert (PPI) information
for the query ligand and drugs that modulate the new tar-
get, and (3) multiple crystallographic structures of the
known target and of the putative new target. Figure 1
summarizes the computational approach, which combines
four methods, each of which measures molecular similarity
or molecular complementarity. Panel (a) depicts the
methods, which produce a set of scores (ligand structural
similarity and PPI similarity) or a single score (docking and
protein pocket similarity). Each score is transformed into a
p value by making use of an empirically computed back-
ground score distribution [8]. Panel (b) illustrates how the
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resulting set of p values are combined to produce a single
overall log-odds score.
Known drugs are the subject of investigation using the
framework we describe in this work. This is because drugs
have the richest annotation information available, includ-
ing both phenotypic and structural information. However,
we envision that the most important application of this
framework is in the pre-clinical evaluation of candidate
molecules. Clearly, the structure-based computations
shown in Fig. 1 can be made for many putative off-targets,
but the framework offers the ability to make use of a wide
variety of phenotypic information, such as the increasingly
common use of multi-target generalized assay panels.
Similarity computations between vectors of biological
assay data have been shown to be related to both structural
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interactions. a Raw scores from
four methodologies (3D
chemical similarity, patient
package insert text comparison,
docking, and pocket similarity)
are converted to p values which
are then combined to yield a
single log-odds score. For 3D
and PPI similarities, the
pairwise similarities are
determined for a test molecule
against a set of ligands that
share a target. One
representative pair for each
method is shown. For docking,
the test molecule is docked into
multiple structures of the target
in question. For protein
similarity, the surfaces of 2
target protein pockets are
compared. b Computation of
log-odds score (S). We compute
the likelihood that the observed
set of p values is extreme using
the multinomial distribution.
The collective p values are
binned (top), and the bin counts
are computed. M is the
likelihood of having observed
such a set of p values, and M* is
the same computation using the
converse probabilities. The Log
Odds score S combines the two.
Positive S indicates that it is
more likely that the molecule in
question shares an activity with
the ligand set than it does not
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from such comparisons can be incorporated into the log-
odds framework. Linkages between a candidate molecule
and an undesirable target or phenotype may suggest
experimentally testable hypotheses that could avoid unde-
sirable off-target effects.
Here, we show how multiple computational methods
explain the mechanistic basis for the relationship between
PPARa and the COX enzymes. We present the first direct
experimental evidence that fibrate drugs whose anti-lipe-
mic effects are mediated through PPARa are also COX
inhibitors in vitro. This new finding suggests that the
known anti-inflammatory effects of fibrates are mediated,
at least in part, through direct inhibition of COX enzymes
in vivo. Taken together, the results demonstrate the utility
of a combined computational approach in identifying and
understanding unexpected interactions between drugs and
biological targets.
Results
We have shown that the combination of molecular struc-
tural similarity combined with similarity computed from
drug package inserts provides improved detection of true
ligand-target interactions over use of single-mode similar-
ity computations when controlling for false detection rates
[9]. The study focused on 602 drugs and 91 diverse bio-
logical targets, with the emphasis being on computational
validation of combining multiple ligand similarity methods
in a blind prediction test on the ChEMBL database. Here,
the focus is on including protein structural information and
prospective validation of predicted interactions.
Data mining putative drug/target relationships
The matrix of 602 drugs crossed against 91 biological
targets from our previous study contained only a small
fraction of cells with previously identified bona fide
interactions. For this work, the remaining potential drug/
target interactions were scored using the combination of
3D and PPI similarity (the most synergistic pair of simi-
larity computations). To avoid focusing on unsurprising
predictions such as the now well-documented target
crosstalk between the ligands of amine-type GPCRs, and to
increase the chances that protein structural information
would be available, we filtered our results to include only
those where the predicted target was an enzyme. Table 1
shows the ten top-ranked predictions, with log-odds scores
ranging from 21.1–11.6.
The top 8 results all had HIV reverse transcriptase (HIV-
RT) as the predicted target. The top 7 predictions were for
nucleotide analog drugs, most of which have viral or
human polymerases as the intended target (but the target of
gemcitabine is ribonucleotide reductase). A review of the
literature showed that four of the HIV-RT activities were
known (entecavir, ribavirin, gemcitabine, valacyclovir),
three had not been tested or published (clofarabine, gan-
ciclovir, levetiracetam), and only one (telbivudine) has
been shown not to have anti-HIV-RT activity in vitro at
clinical concentrations. The confirmatory literature on the
nucleotide analog predictions was encouraging, but the
predictions themselves were not terribly surprising and
have not been experimentally tested in this work.
However, the question of a linkage between PPARa and
the COX enzymes, for which multiple protein structures
were available, offered a surprising prediction and an
opportunity to explore the value of additional information.
Gemfibrozil was present in our database as a free acid, as
depicted in Fig. 2. A scan of our database identified two
other fibrates (clofibrate and fenofibrate), but their struc-
tures were both represented by ester prodrug formulations.
In vivo, the ester prodrugs are rapidly and completely
converted by esterases to clofibric and fenofibric acid,
respectively [16, 17]. Consequently, all computations dis-
cussed hereafter were performed on the free acid forms of
all three fibrates. Figure 2 shows structures of the acids and
Table 1 Top 10 log-odds predictions for enzyme targets
Drug Known target Predicted target 3D?PPI log-odds Comment on prediction
Entecavir HBV pol/RT HIV-RT 21.1 Confirmed [10]
Telbivudine HBV pol/RT HIV-RT 20.7 No activity at clinical conc. [11]
Ribavirin HCV RNA pol HIV-RT 16.8 Confirmed [12]
Gemcitabine RNR HIV-RT 15.2 Supported [13]
Clofarabine DNA pol HIV-RT 14.4 Not tested
Valacyclovir HSV DNA pol HIV-RT 13.3 Confirmed [14]
Ganciclovir HSV DNA pol HIV-RT 13.1 Not tested
Levetiracetam SV2 HIV-RT 12.9 Not tested
Gemfibrozil PPARa COX-1 11.6 Shown in this work
Gemfibrozil PPARa COX-2 11.6 Shown in this work
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also illustrates the optimal 3D overlay between fenofibric
acid (cyan) and indomethacin (tan), corresponding to a raw
score of 8.4 (equivalent to a p value of 0.01). Clofibric acid
and fenofibric acid yielded 3D log-odds against the COX
enzymes of 7.5 and 3.9, respectively. The PPI log-odds for
fenofibric acid against the COX enzymes was 5.9 (PPI
similarity could not be computed for clofibric acid due to
the lack of a machine-readable package insert). Using all
available ligand-based information, the overall log-odds
scores for gemfibrozil, clofibric acid, and fenofibric acid
were: 11.6, 7.5, and 7.0, respectively. To put these numbers
in perspective, a systematic blind prediction test [9] sug-
gested that log-odds scores of greater than 5.0 yielded
correct ligand to target linkages 40–50 % of the time, with
an upper bound on the false positive prediction rate of
roughly 1–3 %.
Synergy between protein structural and ligand-based
information
Given the availability of multiple experimentally deter-
mined protein structures for both PPARa and the COX
enzymes, we assessed how the inclusion of protein struc-
tural information quantitatively affected the strength of the
predicted association.
Multi-structure docking
Molecular docking was performed using a standard multi-
structure protocol against both COX-1 and COX-2. The
protocol employs multiple conformations of a given bind-
ing pocket and has been shown to significantly improve
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Fig. 2 PPARa and COX
ligands. a 2D structures of three
PPARa agonists. b List of 21
NSAIDs annotated as COX
inhibitors, with a representative
2D structure (indomethacin).
c Optimal 3D superimposition
of fenofibric acid (cyan) and
indomethacin (tan). The thin
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spatially-distinct binding pockets, the cyclooxygenase site
and the peroxidase site, each performing a separate enzy-
matic reaction. The cyclooxygenase site converts arachi-
donic acid to prostaglandin G2 and is the relevant binding
site here. This site includes a hydrophobic channel, with a
nominal difference of one residue between the COX iso-
zymes, but the COX-2 site is 20 % larger [19].
The COX protein structures for docking included those
with bound NSAIDs. For COX-1, these included PDB
codes 2OYU, 3KK6, 3N8X, and 3N8Z (complexes with,
respectively, an indomethacin analog, celecoxib, nimesu-
lide, and flurbiprofen). The COX-2 structures were 1PXX,
3LN1, 3NT1, 3RR3, and 4COX, which are co-complexes
with diclofenac, celecoxib, naproxen, flurbiprofen, and
indomethacin. Protein pocket variants were mutually
aligned using pocket similarity, as done previously [18].
The docking results were similar for COX-1 and COX-2,
so representative COX-2 results are presented in Fig. 3.
Panel (a) shows the 5 aligned COX-2 proteins (ribbons)
with the cognate flurbiprofen ligand (tan sticks) of 3RR3.
The labeled amino acids (light green, thin sticks) were
previously identified as interacting with flurbiprofen in the
co-crystal structure [20]. Specifically, the carboxylate of
the drug forms a salt bridge with Arg-120 and a hydrogen
bond with Tyr-355. The distal aryl ring forms van der
Waals contacts with Gly-526–Ala-527 and stacks against
Tyr-385. Note that the COX-2 binding pocket is relatively
rigid, with sidechains exhibiting little movement on bind-
ing small inhibitors.
Figure 3b shows the highest scoring docked pose of
gemfibrozil (cyan) relative to the native pose of flurbipro-
fen (tan) in 3RR3. Of the three PPARa ligands, gemfibrozil
yielded the most significant scores, corresponding to
p values B0.01 against both enzyme isoforms. The other
two ligands exhibited similar behavior, both in a numerical
sense and in terms of the specific interaction geometry
mimicking that seen with native COX inhibitors. Panel
(c) shows the highest scoring docked pose of clofibric acid
(cyan) relative to the native pose of flurbiprofen (tan) in
3RR3. Panel (d) shows the highest scoring docked pose of
fenofibric acid (cyan) relative to the native pose of indo-
methacin (tan) in 4COX. The relative alignments between
the fibrates and NSAIDs that were derived from the
docking computations mirrored those seen from the 3D
molecular similarity computations (see Figs. 1, 2).
As is often the case in non-native ligand docking, the
use of multiple conformational variants of the proteins was
important, despite the apparent lack of variation in the
pockets by eye. The top poses for gemfibrozil and clofibric
acid came from the flurbiprofen co-crystal structures
(3N8Z and 3RR3). In contrast, the top docking scores for
fenofibric acid resulted from the indomethacin structures
(2OYU and 4COX). Collectively, the docking experiments
strongly supported the hypothesis that PPARa agonists are
COX ligands and suggested rational poses for the fibrates
in the cyclooxygenase pocket.
Protein binding site similarity
Given the ligand similarity and docking results, one would
expect that there is some degree of binding pocket simi-
larity between PPARa and the cyclooxygenase site of
COX-1 and COX-2. These proteins share no sequence
similarity, either in a global sense, or at the level of the
binding sites in question. Sequence comparison using
BLASTp of Q07869 (PPARa) against Q05769 (COX-2)
yielded just two short matches, with overall coverage of
just 8 %, each with E-values suggesting no significant
match ([0.5). Full sequence alignment, using Needleman–
Wunsch, produced just 15 % sequence identity, a level not
considered to indicate statistically significant sequence
similarity (N–W global protein alignment computed at
blast.ncbi.nlm.nih.gov). In cases such as this, structural
similarity may still exist, and the PSIM method has been
shown to have utility in cases where sequence-based
approaches do not [7, 21]. PSIM is a local, surface-based
method to compare protein binding sites, and it is analo-
gous to the small molecule comparison method whose
results are illustrated in Figs. 1 and 2. Note, however, that
the two proteins do not share the same SCOP/CATH fold
and have a template-modeling structural alignment score of
less than 0.4 (using TM-align, a global comparison
method) [22].
In order to compare the PPARa and COX protein
pockets, all 14 human PPARa structures were obtained:
1I7G, 1K7L, 1KKQ, 2NPA, 2P54, 2REW, 2ZNN, 3ET1,
3FEI, 3G8I, 3KDT, 3KDU, 3SP6, 3VI8. The COX
enzymes were represented by the nine structures used for
docking (see above). An all-by-all similarity comparison of
the 23 protein pockets was computed, and the PSIM raw
similarity scores were converted to p values, as previously
described [7]. Figure 4a shows the alignment of the highest
scoring non-cognate protein pair, 2REW (PPARa in purple
ribbon) crystallized with BMS-631707 (cyan), and 3RR3
(COX-2 in green ribbon) crystallized with flurbiprofen
(tan). The PSIM score was 6.0, corresponding to a p value
of 6.7e-04. The maximal PSIM score for the COX iso-
zymes was 9.0 (3N8Z and 3RR3) with a p value 0.001.
The labeled amino acids shown in thin sticks in Fig. 4a
were identified as interacting with bound ligands and likely
contribute to the similarity of the PPARa and COX-2
pockets. Specifically, PPARa Ser-280, Tyr-314, and
His440 form hydrogen bonds with the carboxylic acid
group of ligands, and Phe-273 and Phe-351 are known to
line the hydrophobic cleft of the PPARa pocket [23–26].
For flurbiprofen in COX-2, the carboxylate of the drug
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forms a salt bridge to Arg-120 and a hydrogen bond to Tyr-
355, and the distal aryl ring of the ligand forms van der
Waals contacts with Gly-526–Ala-527 and stacks against
Tyr-385 [20]. COX-2 Ser-530 also interacts with the distal
aryl ring of flurbiprofen and is the residue that is selectively
acetylated by aspirin. Note the coincidence of ligand-
binding residue pairs between the aligned pockets. For
example, PPARa Tyr-314 overlaps with COX-2 Tyr-355
and PPARa Phe-351 overlaps with COX-2 Tyr-385. Figure
4b shows the 3D surface similarity of the pockets with thin
sticks indicating regions of similarity, steric (green), blue
(positive charge), and red (negative charge). There is a
region of prominent polar similarity near the carboxylates
of the bound ligands, and the green sticks indicate a sig-
nificant common steric shape. The common pocket volume
between PPARa and COX-2 is highlighted in Fig. 4c, d
where the protein surfaces are shown mesh (COX-2 in red
and PPARa in green). PPARa and COX-2 clearly share
quantitatively similar binding pockets, both in shape and
surface charge, despite the lack of any primary sequence
relationship between the two proteins.
Table 2 summarizes the number of p values and the log-
odds predictions from the individual methods as well as the
combination of the methods that relate gemfibrozil to the
COX enzymes. Each individual method predicts the inter-
action, and the combined log-odds of 15.8 is much stronger
than any single method alone. Beyond lending quantitative
support to the hypothesized PPARa=COX linkage, the
results of the computations offer insight into the structural
basis for ligand cross-talk, as illustrated in Figs. 3 and 4.
Gemfibrozil docked into COX-2
Clofibric acid docked into COX-2 Fenofibric acid docked into COX-2









Fig. 3 Multi-structure docking of PPARa ligands into the cycloox-
ygenase site of COX-2. a Alignment of 5 COX-2 structures (ribbon)
with key residues in thin sticks (light green). The cognate flurbiprofen
ligand of 3RR3 is in tan sticks and the 2D structure is shown in the
lower left. b Highest scoring docked pose of gemfibrozil (cyan)
relative to native pose of flurbiprofen (tan) in 3RR3, p value = 6.0e-
03. c Highest scoring docked pose of clofibric acid (cyan) relative to
native pose of flurbiprofen (tan) in 3RR3. d Highest scoring docked
pose of fenofibric acid (cyan) relative to the native pose of
indomethacin (tan) in 4COX
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COX enzyme assays
In vitro assays were performed to directly test if gemfi-
brozil, clofibric acid, or fenofibric acid were COX inhibi-
tors. The source of the enzymes for the assays were
microsomal preparations from Sf9 cells transfected with
recombinant human COX-1 or COX-2 [27], and the assay
measured the conversion of the substrate arachidonic acid
to PGE2. The steady state mean maximum plasma con-
centrations following the typical prescribed dose for the
fibrates in this study are 240 lM for gemfibrozil [28],
1,000 lM for clofibric acid [29], and 50 lM for fenofibric
acid [17]. Tests were performed at concentrations of 250
and 1,000 lM, based on the in vivo plasma concentrations.
All three drugs exhibited inhibition of COX-1 at 250 lM:
48, 18, and 14 % for, respectively, fenofibric acid, gemfi-
brozil, and clofibric acid. At the higher concentration,
inhibition increased for fenofibric acid (57 %) against
COX-1. For COX-2, fenofibric acid also showed dose-






















3D similarity overlay of PPAR and COX-2 pocketsLigand binding residues in aligned PPAR and COX-2 pockets
Overlapping volume of PPAR and COX-2 pockets
Fig. 4 Binding site surface similarity between PPARa and COX-2.
a Alignment of PPARa (2REW in purple ribbon) crystallized with
BMS-631707 (cyan), and COX-2 (3RR3 in green ribbon) crystallized
with flurbiprofen (tan). In thin sticks with labels are residues known to
interact with bound ligands. PSIM score = 0.6, p value = 6.7e-04.
b Thin sticks indicate regions of significant surface similarity, green-
steric, blue-positive charge, red-negative charge. c In mesh overlay
are the surfaces of the aligned proteins revealing the common volume
of the binding pockets of COX-2 (red) and PPARa (green). d 90
horizontal rotation of (c)
Table 2 Log-odds predictions for gemfibrozil interacting with COX
enzymes
Method Number of p values Log-odds
3D Similarity 21 7.2
PPI similarity 21 8.7
Docking 2 3.4
Pocket similarity 2 3.4
Combined 46 15.8
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For clofibric acid, marginal inhibition was seen at the
higher concentration for COX-1 and at both concentrations
for COX-2 (5, 13, and 11 %, respectively). Gemfibrozil
also showed only marginal COX-1 inhibition at the higher
concentration (8 %), and it exhibited a paradoxical
behavior against COX-2, nominally increasing enzyme
activity at the 250 and 1,000 lM concentrations (by 41 and
66 %). Such mixed phenomena are common in in vitro
COX assays. In a recent study testing the COX modulatory
activity of bioflavinoids, some ligands had maximum effect
at 250 lM with a decline in activity at higher concentra-
tions [30]. In addition, several compounds stimulated COX
activity, and some compounds had opposite effects on
COX-1 versus COX-2.
Because fenofibric acid showed the greatest COX
inhibitory activity, full inhibitor titration assays were per-
formed. Nine concentrations were tested, down to a con-
centration of 3 lM, using serial threefold dilution. The
titration curves are shown in Fig. 5. The IC50 of fenofibric
acid for COX-1 was 950 lM (Hill coefficient 0.7). This is
comparable to that of NSAIDs such as acetaminophen and
salicylic acid. Those drugs were shown to have IC50 values
of  200 and 500 lM, respectively, in a microsomal assay
for COX-1 [31]. The effect of fenofibric acid on COX-2
was weaker by at least twofold, but still clearly dose-
dependent, with a Hill coefficient of 1.2. For context in
terms of selectivity, acetaminophen exhibits similar
behavior, with recent data yielding IC50 values of 130 lM
for COX-1 and 5,900 lM for COX-2 [32].
Discussion
Our earlier work reported a probabilistic framework for
relating ligands to putative off-targets, where the results of
multiple types of ligand-based similarity computations
were shown to have synergistic properties [8, 9]. Those
studies made use of retrospective cross-validation and
blind-testing approaches for methodological evaluation.
Here, the focus has been on the prospective testing of
predictions made using a generalization of the framework,
which combines ligand similarity from both structure and
text-based descriptions of clinical effects, docking com-
putations, and protein pocket comparisons. Conceptually,
the important contributions involve the exploitation of new
information types that can be derived from protein struc-
tural information. Docking was used in an analogous
fashion to ligand comparisons, with docking scores making
a direct linkage to a putative target based on computations
involving ligand fit into established active sites. The par-
allel ligand-based linkage makes comparisons between a
ligand of interest to established small-molecule modulators
of the putative target. Linkage of a different type, directly
from one target to another, was made through the use of
protein binding site comparisons. At present, we do not
have an estimate for how often such surprising local
structural similarities will exist between pairs of apparently
unrelated proteins, but comprehensive computations on
pairs of liganded protein binding sites are planned, in part
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Fig. 5 COX inhibitory activity of fenofibric acid. a Titration of COX-
2 inhibitory activity, resulting in an IC50 of 950 lM. b Same plot for
COX-2 inhibitory activity, resulting in a nominal IC50 of  2.2 mM.
The IC50 was not determined definitively because assay detection
was hampered at the two highest concentrations tested (marked with
circles)
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The particular prospective result we describe is that
PPARa drugs such as fenofibric acid are also COX inhib-
itors at concentrations that are likely to be physiologically
relevant in clinical application. Enzyme assay results
showed that fibrates are indeed COX ligands in vitro and
that fenofibric acid in particular has inhibitory COX
activity similar to that of the less potent NSAIDs. The
PPAR receptors are clinically important in anti-lipemic
therapy, mediating one of the mechanisms by which fi-
brates lower high plasma triglycerides [33]. Fibrate use has
more than doubled in the United States over the past dec-
ade, to nearly 1 % of the population [34]. Widespread and
increasing fibrate use is driven by the heavy mortality
burden of cardiovascular disease [35], underlining the need
for understanding pharmacological crosstalk in this target
and ligand category. PPARa specifically upregulates the
expression of genes for both the transporters and enzymes
involved in the b-oxidation of fatty acids [36].
In addition to anti-lipemic benefits, PPARs and fibrates
have been shown to have anti-inflammatory properties [37–
39]. Fenofibrate was shown to reduce serum levels of
tumor necrosis factor-a (TNF-a) and interferon c (IFN-c)
in hyperlipidemia patients [40]. Similarly, gemfibrozil was
shown to increase survival in mice with an induced sys-
temic inflammatory illness, likely through reducing
excessive cytokine production [41]. In addition to reducing
the expression of the inflammation mediators TNF-a and
IFN-c, PPARa was demonstrated to negatively regulate
COX-2 gene transcription [42]. Our results suggest that
some of the anti-inflammatory effects of the fibrates may
be due to direct interaction with the COX enzymes. That
one of the effects of PPARa activation is to downregulate
COX-2 may point to a more general phenomenon. The
binding sites of ligand-modulated transcription factors may
have evolved to be sensitive to ligands of enzymes and
receptors that are downstream of the transcription factors.
This will be explored in future work by considering the
similarity of ligand binding sites of transcription factors to
those of the proteins they regulate.
A linkage between the COX enzymes and the PPARs
had been noted by earlier investigators, stimulated by the
observation that treatment of preadipocyte cell lines with
indomethacin resulted in terminal differentiation to adi-
pocytes [43]. Because PPARc was known to be a regulator
of adipocyte differentiation, indomethacin and other COX
inhibitors were tested for PPAR modulatory activity.
Indomethacin, fenoprofen, ibuprofen, and flufenamic acid
were shown to be PPARc and PPARa agonists [44]. The
biochemical contribution here is novel in that we have
shown the converse: that established PPAR ligands have
meaningful activity against the COX enzymes. Recently,
dual-action anti-inflammatory small molecules have been
sought to simultaneously inhibit the COX enzymes and
activate the PPARs [45]. The structural relationships we
have established may provide insight into ligand design.
In this case, computations involving ligand similarity,
docking, and protein pocket comparison each indepen-
dently produced correspondences that all mutually agreed.
Each produced a correspondence of parts, whether ligand
to ligand, ligand to protein, or protein to protein. Given that
the structural information included co-crystal structures for
both targets, the cross-correspondences may be visualized
(see Figs. 2, 3, 4) and seem to agree nearly atom for atom.
For the ligand similarity and docking computations, the
correspondence, while striking, is not surprising given that
the molecules in question are relatively small organic
acids. The protein alignment that gave rise to the signifi-
cant pocket similarity score was more subtle, requiring the
correspondence of an Arg/Tyr acid recognition element for
COX-2 to a Ser/Tyr/His triad in PPARa. Further, the
hydrophobic PPARa pocket is only ‘‘open’’ in a single
structure within the PDB, one which exhibits marked
movement of a key residue in the binding site. Figure 6
shows the 14 aligned PPARa proteins in ribbons with Phe-
273 of each in thin sticks, with the ligand of the aligned
3RR3 COX-2 structure shown as well. Within the 2REW
variant of PPARa, Phe-273 is rotated out of the space that
is occupied by the aligned flurbiprofen. The structural
importance of this residue has been highlighted with





Alignment of 14 PPAR structures
Fig. 6 Shown is the alignment of 14 PPARa structures (ribbon) with
Phe-273 in thin sticks. Of the 14 structures, only 2REW has Phe-273
(light green) in an orientation that does not occupy the space of the
distal aryl ring of the flurbiprofen ligand (tan) of the aligned 3RR3
COX-2 protein (not shown)
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ligand binding [46], and importance in direct ligand
interactions [23, 24]. Several pairs of COX and PPARa
structures produced significant protein similarity scores,
but the highest score arose from the particular case where
Phe-273 was not occupying the ligand space of the aligned
COX enzyme.
Each computational modality used here is subject to
different biases and limitations, so the ability to combine
diverse sources of information is a critical feature. Scores
from any computations that relate a compound to another, a
compound to a target, or a target to another target can be
converted into probabilities. This only requires that each
score has a monotonic interpretation (i.e. that a higher
score suggests higher likelihood of linkage than a lower
score, or vice versa).
Data associated with historical medicinal chemistry dis-
covery projects may include assay data against particular
targets, pre-clinical animal testing results (including textual
descriptions of observed effects), or the results of broad
standardized assay panels for pre-clinical evaluation. All
such data should be amenable to the framework described
here. We believe that hypotheses of off-target effects that are
made based on such computations, when investigated
experimentally, have the potential to reduce the frequency of
discovering serious side effects during human trials.
Methods
Molecular data sets
The SPDB database of annotated drugs and targets has
been described [8, 9]. Structures obtained from the PDB
were downloaded from http://www.rcsb.org/pdb as Bio-
logical Assemblies.
Computational methods
Surflex computational methods have been described in
detail: 3D similarity [1, 47], PPI similarity and the log-odds
computation including conversion of raw similarity scores
to p values [8, 9], docking including multiple structures [6,
18, 48], and protein similarity including conversion of raw
similarity scores to p values [7, 21]. All computations
involving ligand similarity, docking, and protein pocket
similarity were made according to standard protocols.
Data, software, and computational protocols are available
by request (see www.jainlab.org for details).
Enzyme assays
COX assays were performed by Cerep Corporation (Red-
mond, WA). Briefly, human recombinant COX-1 and
COX-2 were expressed in Sf9 cells and microsomes were
prepared from the transfected cells as described [27].
Reactions proceeded for 5 min at room temperature with
control or test compounds. The control inhibitor com-
pounds were diclofenac for COX-1 and NS398 for COX-2.
The assay measured the conversion of the substrate ara-
chidonic acid to PGE2, and the detection method for PGE2
concentration was homogeneous-time-resolved-fluores-
cence [49].
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